Strata Critical Medical annual r&d spending
2019
2020
2021
2022
2023
2024
Strata Critical Medical R&D Spending Growth & History (SRTA)
Strata Critical Medical's r&d spending was $3.2M for fiscal 2024.
View full Strata Critical Medical company overviewStrata Critical Medical annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $3.2M | −$1.4M | −31.19% |
| 2023 | 2023-12-31 | $4.6M | −$918,000 | −16.56% |
| 2022 | 2022-12-31 | $5.5M | — | — |
| 2021 | 2021-09-30 | $1.7M | $823,000 | +95.59% |
| 2020 · Sep 30 | 2020-09-30 | $861,000 | $110,000 | +14.65% |
| 2019 · Sep 30 | 2019-09-30 | $751,000 | — | — |
Strata Critical Medical quarterly r&d spending
Q2.20
Q1.21
Q2.21
Q4.21
Q1.22
Q2.22
Q3.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.0M | $91,000 | +9.95% |
| Q3 2025 | 2025-09-30 | $453,000 | $36,000 | +8.63% |
| Q2 2025 | 2025-06-30 | $915,000 | −$56,000 | −5.77% |
| Q1 2025 | 2025-03-31 | $812,000 | $142,000 | +21.19% |
| Q4 2024 | 2024-12-31 | $1.1M | $138,000 | +13.97% |
| Q3 2024 | 2024-09-30 | $417,000 | −$659,000 | −61.25% |
| Q2 2024 | 2024-06-30 | $971,000 | −$469,000 | −32.57% |
| Q1 2024 | 2024-03-31 | $670,000 | −$453,000 | −40.34% |
| Q4 2023 | 2023-12-31 | $988,000 | −$634,000 | −39.09% |
| Q3 2023 | 2023-09-30 | $1.1M | −$950,000 | −46.89% |
| Q2 2023 | 2023-06-30 | $1.4M | $378,000 | +35.59% |
| Q1 2023 | 2023-03-31 | $1.1M | $288,000 | +34.49% |
| Q4 2022 | 2022-12-31 | $1.6M | $920,000 | +131.05% |
| Q3 2022 · Sep 30 | 2022-09-30 | $2.0M | $1.2M | +140.05% |
| Q3 2022 · Jun 30 | 2022-06-30 | $1.1M | $739,000 | +228.79% |
| Q2 2022 | 2022-03-31 | $835,000 | $546,000 | +188.93% |
| Q1 2022 | 2021-12-31 | $702,000 | — | — |
| Q4 2021 | 2021-09-30 | $844,000 | — | — |
| Q2 2021 | 2021-06-30 | $323,000 | $103,000 | +46.82% |
| Q1 2021 | 2021-03-31 | $289,000 | — | — |
| Q2 2020 | 2020-06-30 | $220,000 | — | — |
Strata Critical Medical r&d spending trends
Between the periods ended 2019-09-30 and 2024-12-31, Strata Critical Medical's r&d spending increased from $751,000 to $3.2M, a change of $2.4M. The latest reported quarter, Q2 2026, shows $1.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Strata Critical Medical source filings ↗